ClinicalTrials.gg
WithdrawnNCT07221513RENEU-PHUpdated May 15, 2026

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

A Phase 2 interventional study of JK07 in HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction and Group 2 Pulmonary Hypertension, sponsored by Salubris Biotherapeutics Inc. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Salubris Biotherapeutics Inc (part of Shenzhen Salubris Pharmaceuticals Co., Ltd.) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Enrollment
1,522nd of 1,601
0 · median 65
Started
2025
with 107 others
Phase 2
227 of 2,157
26 open now
Registered
2,051st of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 1,522nd largest by enrollment of the 1,601 interventional ones that give a count, is one of 108 that started in 2025, is one of 227 in phase 2, and was the 2,051st registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.

At least 20 and up to approximately 30 participants will be enrolled and receive JK07 high dose in this open-label trial.

03

Conditions studied

  • HFrEF - Heart Failure With Reduced Ejection Fraction
  • HFpEF - Heart Failure With Preserved Ejection Fraction
  • Group 2 Pulmonary Hypertension

Keywords

  • Heart Failure
  • Heart Failure with Reduced Ejection Fraction
  • HFrEF
  • HFpEF
  • Heart Failure with Preserved Ejection Fraction
  • Group 2 Pulmonary Hypertension
  • Pulmonary Hypertension
  • cpcPH
  • Heart Failure NYHA Class III
  • Heart Failure NYHA Class II
  • Systolic Heart Failure
  • Diastolic Heart Failure
  • Neuregulin 1
  • NRG-1
  • ErbB4
  • HER3
  • HER4
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with HF Class II-III.
  • Participants will be classified as having HFrEF ( ≤ 40%) or HFpEF (LVEF >40% and ≤70%).
  • Right heart catheterization (RHC) based evidence of cpcPH:
  • PVR ≥2.5 WU; AND
  • mPAP ≥25 mmHg; AND
  • PAWP ≥16 mmHg

Key Exclusion Criteria:

  • Diagnosis of PH in World Health Organization (WHO) Group 1, WHO Group 3, WHO Group 4, or WHO Group 5.
  • to RHC that can be left in place for approximately 6 hours.
  • A diagnosis of pre-existing lung disease including congenital abnormalities, full or partial pneumonectomy, or previous therapeutic radiation of lungs or mediastinum.
  • (BMI) >45 kg/m² at screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    JK07 high dose

    JK07 administered by intravenous (IV) infusion

    Drug: JK07

Interventions

  • DrugJK07

    JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of TEAEs [Safety and tolerability]

    Incidence and severity of treatment emergent adverse events

    Time frame: Study entry through week 26

Secondary outcomes

  1. Pharmacokinetic - Cmax

    Characterize the JK07 PK profile through Peak Plasma Concentration (Cmax) following IV administration

    Time frame: Study entry through week 26

  2. Pharmacokinetics - Tmax

    Characterize the JK07 PK profile through Time to Peak Plasma Concentration (Tmax) following IV administration

    Time frame: Study entry through week 26

  3. Pharmacokinetics - AUC0-last

    Characterize the JK07 PK profile through area under the concentration-time curve from time 0 to last quantifiable concentration (AUC0-last) following IV administration

    Time frame: Study entry through week 26

  4. Pharmacokinetics - AUC0-inf

    Characterize the JK07 PK profile through area under the concentration-time curve from time 0 to infinity (AUC0-inf) following IV administration

    Time frame: Study entry through week 26

  5. Pharmacokinetics - t1/2

    Characterize the JK07 PK profile through half-life (t1/2) following IV administration

    Time frame: Study entry through week 26

  6. Pharmacokinetics - λz

    Characterize the JK07 PK profile through elimination rate constant (λz) following IV administration

    Time frame: Study entry through week 26

  7. Pharmacokinetics - CL

    Characterize the JK07 PK profile through systemic clearance (CL) following IV administration

    Time frame: Study entry through week 26

  8. Pharmacokinetics - Vz

    Characterize the JK07 PK profile through volume of distribution (Vz) following IV administration

    Time frame: Study entry through week 26

07

Study locations

1 site
  • Saint Francis Heart and Vascular Institute
    Tulsa, Oklahoma 74136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Apr 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Oct 28, 2025
StartActual
Dec 15, 2025
Primary completionActual
Apr 16, 2026
CompletionActual
Apr 16, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07221513
Responsible party
Sponsor
First posted
Oct 28, 2025
Start date
Dec 15, 2025
Primary completion
Apr 16, 2026
Completion
Apr 16, 2026
Last update
May 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JK07

Start the discussion